The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2016 | How do novel agents affect allogeneic transplantation in CLL?
At the 42nd Annual Meeting of the European Society for Blood and Marrow Transplantation, held in Valencia, Spain, John Gribben, MD, from Barts Cancer Institute, London, UK, discusses how novel agents, like ibrutinib and idelalisib, lead to a reduction of allogeneic transplants in chronic lymphocytic leukemia (CLL). These new, effective treatments raise a question: Who are the patients and when allogeneic transplants should be offered?
